Cellebrite DI Ltd. Publishes Q1 2025 MD&A Report

Reuters
2025/05/15
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> DI Ltd. Publishes Q1 2025 MD&A Report

Cellebrite DI Ltd. reported a strong 23% year-on-year growth in Annual Recurring Revenue $(ARR)$ for the first quarter, alongside a 34% increase in adjusted EBITDA, resulting in a 22% margin. This performance supported a Rule of X rating of 45 for the quarter and 48 over the trailing twelve months, aligning with the company's target range of 45-50. The company is focused on maintaining growth while managing spending to support bottom-line objectives. Key developments include robust year-over-year growth in ARR and revenue, driven by increasing demand from intelligence and defense sectors in response to the growing sophistication of digitally-enabled crime. Additionally, the company reported positive progress with its Inseyets migration and strategic penetration of its Guardian and Pathfinder products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10